The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Flying under the radar: the new wave of BCR–ABL inhibitors
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486 · cited 1×
“cgi?id=211980">lung cancer (NSCLC) carrying mutant variants of EGF”
BackgroundEGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., Lydon, N. B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441401 · Cited by 5,243
Self-citationGain-of-Function Mutations of c- kit in Human Gastrointestinal Stromal Tumors
Hirota, S., Isozaki, K., Moriyama, Y., Hashimoto, K., Nishida, T., Ishiguro, S., Kawano, K., Hanada, M., Kurata, A., Takeda, M., et al. (1998) · Science · doi:10.1126/science.279.5350.577 · Cited by 4,490
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
Druker, B. J., Guilhot, F., O'Brien, S. G., Gathmann, I., Kantarjian, H., Gattermann, N., Deininger, M. W. N., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,488
Self-citationClinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Self-citationFusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K. G., Shapiro, D. N., Saltman, D. L., & Look, A. T. (1994) · Science · doi:10.1126/science.8122112 · Cited by 2,409
Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor
Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A., & Connelly, P. A. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.695 · Cited by 1,939
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W. H., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,892
Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor
Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D., & Sawyers, C. L. (2004) · Science · doi:10.1126/science.1099480 · Cited by 1,796
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T., Bornmann, W., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,780
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Self-citationDaley, G. Q., Van Etten, R. A., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 1,756
The Conformational Plasticity of Protein Kinases
Huse, M., & Kuriyan, J. (2002) · Cell · doi:10.1016/s0092-8674(02)00741-9 · Cited by 1,752
Cools, J., DeAngelo, D. J., Gotlib, J., Stover, E. H., Legare, R. D., Cortes, J., Kutok, J., Clark, J., Galinsky, I., Griffin, J. D., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025217 · Cited by 1,718
Self-citationShah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,612
Fused transcript of abl and bcr genes in chronic myelogenous leukaemia
Shtivelman, E., Lifshitz, B., Gale, R. P., & Canaani, E. (1985) · Nature · doi:10.1038/315550a0 · Cited by 1,611
Mitotic kinases as regulators of cell division and its checkpoints
Nigg, E. A. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35048096 · Cited by 1,547
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan-Jacob, S. W., Ray, A., Huntly, B., Fabbro, D., Fendrich, G., Hall-Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,492
Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL
Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S., Wassmann, B., Tanaka, C., Manley, P., Rae, P., Mietlowski, W., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055104 · Cited by 1,344
Self-citationLombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A. M., Das, J., Doweyko, A. M., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049486a · Cited by 1,297
Tyrosine Kinase Activity and Transformation Potency of bcr-abl Oncogene Products
Lugo, T. G., Pendergast, A.-M., Muller, A. J., & Witte, O. N. (1990) · Science · doi:10.1126/science.2408149 · Cited by 1,281
The protein tyrosine kinase family of the human genome
Robinson, D. R., Wu, Y.-M., & Lin, S.-F. (2000) · Oncogene · doi:10.1038/sj.onc.1203957 · Cited by 1,167
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
Kerkelä, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., Walters, B., Shevtsov, S., Pesant, S., Clubb, F. J., et al. (2006) · Nature Medicine · doi:10.1038/nm1446 · Cited by 1,159
Hofstra, R. M. W., Landsvater, R. M., Ceccherini, I., Stulp, R. P., Stelwagen, T., Luo, Y., Pasini, B., Hoppener, J. W. M., van Amstel, H. K. P., Romeo, G., et al. (1994) · Nature · doi:10.1038/367375a0 · Cited by 1,149
Sawyers, C. L. (2002) · Blood · doi:10.1182/blood.v99.10.3530 · Cited by 1,146
The cellular geography of Aurora kinases
Carmena, M., & Earnshaw, W. C. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1245 · Cited by 1,139
Rational design of inhibitors that bind to inactive kinase conformations
Liu, Y., & Gray, N. S. (2006) · Nature Chemical Biology · doi:10.1038/nchembio799 · Cited by 1,094
Crystal structure of the tyrosine kinase domain of the human insulin receptor
Hubbard, S. R., Wei, L., & Hendrickson, W. A. (1994) · Nature · doi:10.1038/372746a0 · Cited by 1,080
Buchdunger, E., Zimmermann, J., Mett, H., Meyer, T., Müller, M., Druker, B. J., & Lydon, N. (1996) · PubMed · Cited by 1,057
Straus, D. (1992) · Cell · doi:10.1016/0092-8674(92)90428-f · Cited by 1,034
Harrington, E. A., Bebbington, D., Moore, J., Rasmussen, R. K., Ajose-Adeogun, A. O., Nakayama, T., Graham, J. A., Demur, C., Hercend, T., Diu-Hercend, A., et al. (2004) · Nature Medicine · doi:10.1038/nm1003 · Cited by 965
Nagar, B., Bornmann, W. G., Pellicena, P., Schindler, T. H., Veach, D. R., Miller, W. T., Clarkson, B. D., & Kuriyan, J. (2002) · PubMed · Cited by 923
Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase
Nagar, B., Hantschel, O., Young, M. A., Scheffzek, K., Veach, D., Bornmann, W., Clarkson, B., Superti-Furga, G., & Kuriyan, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00194-6 · Cited by 879
The Chronic Myelogenous Leukemia-Specific P210 Protein Is the Product of the bcr / abl Hybrid Gene
Ben-Neriah, Y., Daley, G. Q., Mes-Masson, A.-M., Witte, O. N., & Baltimore, D. (1986) · Science · doi:10.1126/science.3460176 · Cited by 806
Tokarski, J. S., Newitt, J. A., Chang, C. Y. J., Cheng, J. D., Wittekind, M., Kiefer, S. E., Kish, K., Lee, F. Y. F., Borzillerri, R., Lombardo, L. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4187 · Cited by 700
Lane, H. A., & Nigg, E. A. (1996) · The Journal of cell biology · doi:10.1083/jcb.135.6.1701 · Cited by 690
Donato, N. J., Wu, J. Y., Stapley, J., Gallick, G., Lin, H., Arlinghaus, R., & Talpaz, M. (2003) · Blood · doi:10.1182/blood.v101.2.690 · Cited by 663
Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL
Azam, M., Latek, R. R., & Daley, G. Q. (2003) · Cell · doi:10.1016/s0092-8674(03)00190-9 · Cited by 613
Hochhaus, A., Kantarjian, H. M., Baccarani, M., Lipton, J. H., Apperley, J. F., Druker, B. J., Facon, T., Goldberg, S. L., Cervantes, F., Niederwieser, D., et al. (2007) · Blood · doi:10.1182/blood-2006-09-047266 · Cited by 609
Self-citationInhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
Carter, T. A., Wodicka, L. M., Shah, N. P., Velasco, A. M., Fabian, M. A., Treiber, D. K., Milanov, Z. V., Atteridge, C. E., Biggs, W. H., Edeen, P. T., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504952102 · Cited by 554
Bhatia, R., Holtz, M., Niu, N., Gray, R., Snyder, D. S., Sawyers, C. L., Arber, D. A., Slovak, M. L., & Forman, S. J. (2003) · Blood · doi:10.1182/blood-2002-09-2780 · Cited by 547
Nosaka, T. (1999) · The EMBO Journal · doi:10.1093/emboj/18.17.4754 · Cited by 491
A Myristoyl/Phosphotyrosine Switch Regulates c-Abl
Hantschel, O., Nagar, B., Guettler, S., Kretzschmar, J., Dorey, K., Kuriyan, J., & Superti-Furga, G. (2003) · Cell · doi:10.1016/s0092-8674(03)00191-0 · Cited by 480
Cortes, J., Rousselot, P., Kim, D.-W., Ritchie, E., Hamerschlak, N., Coutre, S., Hochhaus, A., Guilhot, F., Saglio, G., Apperley, J., et al. (2007) · Blood · doi:10.1182/blood-2006-09-046888 · Cited by 416
Self-citationGolas, J. M., Arndt, K. T., Etienne, C., Lucas, J., Nardin, D., Gibbons, J. J., Frost, P., Ye, F., Boschelli, D. H., & Boschelli, F. (2003) · PubMed · Cited by 408
Hu, Y., Liu, Y., Pelletier, S., Buchdunger, E., Warmuth, M., Fabbro, D., Hallek, M., Van Etten, R. A., & Li, S. (2004) · Nature Genetics · doi:10.1038/ng1343 · Cited by 405
Src Family Tyrosine Kinases and Growth Factor Signaling
Abram, C. L., & Courtneidge, S. A. (2000) · Experimental Cell Research · doi:10.1006/excr.1999.4732 · Cited by 391
Allosteric inhibitors of Bcr-abl–dependent cell proliferation
Adrián, F. J., Ding, Q., Sim, T., Velentza, A., Sloan, C., Liu, Y., Zhang, G., Hur, W., Ding, S., Manley, P., et al. (2006) · Nature Chemical Biology · doi:10.1038/nchembio760 · Cited by 381
Puttini, M., Coluccia, A. M. L., Boschelli, F., Cleris, L., Marchesi, E., Donella-Deana, A., Ahmed, S., Redaelli, S., Piazza, R., Magistroni, V., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1199 · Cited by 375
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias
Gambacorti-Passerini, C. B., Gunby, R. H., Piazza, R., Galietta, A., Rostagno, R., & Scapozza, L. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)00979-3 · Cited by 373
Guilhot, F., Apperley, J., Kim, D.-W., Bullorsky, E. O., Baccarani, M., Roboz, G. J., Amadori, S., de Souza, C. A., Lipton, J. H., Hochhaus, A., et al. (2007) · Blood · doi:10.1182/blood-2006-09-046839 · Cited by 371
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent
Gumireddy, K., Reddy, M. V. R., Cosenza, S. C., Nathan, R. B., Baker, S. J., Papathi, N., Jiang, J., Holland, J., & Reddy, E. P. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.009 · Cited by 367
Giles, F. J., Cortes, J., Jones, D., Bergstrom, D., Kantarjian, H., & Freedman, S. J. (2007) · Blood · doi:10.1182/blood-2006-05-025049 · Cited by 364
Self-citationHennequin, L. F., Allen, J., Breed, J., Curwen, J., Fennell, M., Green, T. P., Lambert-van der Brempt, C., Morgentin, R., Norman, R. A., Olivier, A., et al. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm060434q · Cited by 364
Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate
Regan, J., Breitfelder, S., Cirillo, P., Gilmore, T., Graham, A. G., Hickey, E., Klaus, B., Madwed, J., Moriak, M., Moss, N., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020057r · Cited by 348
Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance
Hochhaus, A., & La Rosée, P. (2004) · Leukemia · doi:10.1038/sj.leu.2403426 · Cited by 336
Tamborini, E., Bonadiman, L., Greco, A., Albertini, V., Negri, T., Gronchi, A., Bertulli, R., Colecchia, M., Casali, P. G., Pierotti, M. A., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.021 · Cited by 324
Burgess, M. R., Skaggs, B. J., Shah, N. P., Lee, F. Y., & Sawyers, C. L. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409770102 · Cited by 313
A Src-Like Inactive Conformation in the Abl Tyrosine Kinase Domain
Levinson, N. M., Kuchment, O., Shen, K., Young, M. A., Koldobskiy, M., Karplus, M., Cole, P. A., & Kuriyan, J. (2006) · PLoS Biology · doi:10.1371/journal.pbio.0040144 · Cited by 309
BIRB796 Inhibits All p38 MAPK Isoforms in Vitro and in Vivo
Kuma, Y., Sabio, G., Bain, J., Shpiro, N., Márquez, R., & Cuenda, A. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414221200 · Cited by 304
Young, M. A., Shah, N. P., Chao, L. H., Seeliger, M., Milanov, Z. V., Biggs, W. H., Treiber, D. K., Patel, H. K., Zarrinkar, P. P., Lockhart, D. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2788 · Cited by 276
Cell cycle targets of Ras/Raf signalling
Kerkhoff, E., & Rapp, U. R. (1998) · Oncogene · doi:10.1038/sj.onc.1202185 · Cited by 260
Corbin, A. S., Rosée, P. L., Stoffregen, E. P., Druker, B. J., & Deininger, M. W. (2003) · Blood · doi:10.1182/blood-2002-12-3659 · Cited by 258
Kimura, S., Naito, H., Segawa, H., Kuroda, J., Yuasa, T., Sato, K., Yokota, A., Kamitsuji, Y., Kawata, E., Ashihara, E., et al. (2005) · Blood · doi:10.1182/blood-2005-06-2209 · Cited by 241
Dai, Y., Rahmani, M., Corey, S. J., Dent, P., & Grant, S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402290200 · Cited by 239
The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells
Klejman, A. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf562 · Cited by 222
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance
Gumireddy, K., Baker, S. J., Cosenza, S. C., John, P., Kang, A. D., Robell, K. A., Reddy, M. V. R., & Reddy, E. P. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408283102 · Cited by 220
Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia
Donato, N. J., Wu, J. Y., Stapley, J., Lin, H., Arlinghaus, R., Aggarwal, B., Shishodin, S., Albitar, M., Hayes, K., Kantarjian, H., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1484 · Cited by 214
Self-citationKantarjian, H. M., Talpaz, M., O'Brien, S., Jones, D., Giles, F., Garcia-Manero, G., Faderl, S., Ravandi, F., Rios, M. B., Shan, J., et al. (2006) · Blood · doi:10.1182/blood-2006-02-004325 · Cited by 208
Self-citationRosée, P. G. L., Corbin, A. S., Stoffregen, E. P., Deininger, M. W., & Druker, B. J. (2002) · PubMed · Cited by 203
Structure‐function relationships in Src family and related protein tyrosine kinases
Superti‐Furga, G., & Courtneidge, S. A. (1995) · BioEssays · doi:10.1002/bies.950170408 · Cited by 200
O'Hare, T., Pollock, R., Stoffregen, E. P., Keats, J. A., Abdullah, O. M., Moseson, E. M., Rivera, V. M., Tang, H., Metcalf, C. A., Bohacek, R. S., et al. (2004) · Blood · doi:10.1182/blood-2004-05-1851 · Cited by 200
Gridelli, C., Aapro, M., Ardizzoni, A., Balducci, L., De Marinis, F., Kelly, K., Le Chevalier, T., Manegold, C., Perrone, F., Rosell, R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.224 · Cited by 196
Hofmann, W.-K., de Vos, S., Elashoff, D., Gschaidmeier, H., Hoelzer, D., Koeffler, H. P., & Ottmann, O. G. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07678-x · Cited by 194
Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.
Danhauser-riedl, S., Warmuth, M., Druker, B. J., Emmerich, B., & Hallek, M. J. (1996) · PubMed · Cited by 182
The Src-selective Kinase Inhibitor PP1 Also Inhibits Kit and Bcr-Abl Tyrosine Kinases
Tatton, L., Morley, G. M., Chopra, R., & Khwaja, A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209321200 · Cited by 174
Cowan-Jacob, S., Guez, V., Fendrich, G., Griffin, J., Fabbro, D., Furet, P., Liebetanz, J., Mestan, J., & Manley, P. (2004) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557043487321 · Cited by 163
Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.
Wisniewski, D. J., Lambek, C. L., Liu, C., Strife, A., Veach, D. R., Nagar, B., Young, M. A., Schindler, T. H., Bornmann, W. G., Bertino, J. R., et al. (2002) · PubMed · Cited by 161
Functional ABCG2 is overexpressed on primary CML CD34+ cells and is inhibited by imatinib mesylate
Jordanides, N. E., Jorgensen, H. G., Holyoake, T. L., & Mountford, J. C. (2006) · Blood · doi:10.1182/blood-2006-02-003145 · Cited by 158
Takayama, N., Sato, N., O’Brien, S. G., Ikeda, Y., & Okamoto, S. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03881.x · Cited by 152
Substrate Competitive Inhibitors of IGF-1 Receptor Kinase
Blum, G., Gazit, A., & Levitzki, A. (2000) · Biochemistry · doi:10.1021/bi001516y · Cited by 151
Dorsey, J. F., Jove, R., Kraker, A. J., & Wu, J. (2000) · PubMed · Cited by 151
Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants
Skaggs, B. J., Gorre, M. E., Ryvkin, A., Burgess, M. R., Xie, Y., Han, Y., Komisopoulou, E., Brown, L. M., Loo, J. A., Landaw, E. M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609239103 · Cited by 142
Hamby, J. M., Connolly, C. J. C., Schroeder, M. C., Winters, R. T., Showalter, H. D. H., Panek, R. L., Major, T. C., Olsewski, B., Ryan, M. J., Dahring, T. K., et al. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm970367n · Cited by 142
Warmuth, M., Simon, N., Mitina, O., Mathes, R., Fabbro, D., Manley, P. W., Buchdunger, E., Forster, K., Moarefi, I., & Hallek, M. J. (2002) · Blood · doi:10.1182/blood-2002-01-0288 · Cited by 134
Warmuth, M., Bergmann, M., Prieß, A., Häuslmann, K., Emmerich, B., & Hallek, M. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.52.33260 · Cited by 120
Huron, D. R., Gorre, M. E., Kraker, A. J., Sawyers, C. L., Rosen, N. X., & Moasser, M. M. (2003) · PubMed · Cited by 118
Pfeifer, H., Waßmann, B., Hofmann, W., Komor, M., Scheuring, U. J., Bruck, P. T., Binckebanck, A., Schleyer, E., Gökbuget, N., Wolff, T. E., et al. (2003) · PubMed · Cited by 118
Azam, M., Nardi, V., Shakespeare, W. C., Metcalf, C. A., Bohacek, R. S., Wang, Y., Sundaramoorthi, R., Piotr Sliz, A., Veach, D. R., Bornmann, W. G., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600001103 · Cited by 107
Cheetham, G. M. T., Charlton, P., Golec, J. M. C., & Pollard, J. R. (2007) · Cancer Letters · doi:10.1016/j.canlet.2006.12.004 · Cited by 107
Yokota, A., Kimura, S. H., Masuda, S., Ashihara, E., Kuroda, J., Sato, K., Kamitsuji, Y., Kawata, E., Deguchi, Y., Urasaki, Y., et al. (2006) · Blood · doi:10.1182/blood-2006-03-013250 · Cited by 102
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
Hatfield, A. K., Owen, S., & Pilot, P. R. (2007) · Nature Medicine · doi:10.1038/nm0107-13a · Cited by 100
Low concentrations of STI571 in the cerebrospinal fluid: a case report
Petzer, A. L., Gunsilius, E., Hayes, M., et al. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03523.x · Cited by 98
Chen, R., Gandhi, V. V., & Plunkett, W. K. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1216 · Cited by 98
Dalgarno, D. C., Stehle, T., Narula, S. S., Schelling, P., van Schravendijk, M. R., Adams, S. E., Andrade, L. J., Keats, J. A., Ram, M. K., Jin, L., et al. (2005) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2005.00316.x · Cited by 87
Summy, J. M., Trevino, J. G., Lesslie, D. P., Baker, C. H., Shakespeare, W. C., Wang, Y., Sundaramoorthi, R., Metcalf, C. A., Keats, J. A., Sawyer, T. K., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0171 · Cited by 83
Stanglmaier, M., Warmuth, M., Kleinlein, I., dos Reis, S. R. C., & Hallek, M. J. (2003) · Leukemia · doi:10.1038/sj.leu.2402778 · Cited by 81
Neville, K. A., Parise, R. A., Thompson, P., Aleksic, A., Egorin, M. J., Balis, F. M., McGuffey, L., McCully, C. L., Berg, S. L., & Blaney, S. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0155 · Cited by 67
Chronic myelogenous leukaemia with p185BCR/ABL expression: characteristics and clinical significance
Ravandi, F., Cortes, J. E., Albitar, M. X., Arlinghaus, R. B., Guo, J. Q., Talpaz, M., & Kantarjian, H. M. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01736.x · Cited by 61
Self-citationWolff, N. C., Veach, D. R., Tong, W. P., Bornmann, W. G., Clarkson, B. D., & Ilaria, R. L. (2005) · Blood · doi:10.1182/blood-2004-09-3534 · Cited by 60
Corbin, A. S., Demehri, S., Griswold, I. J., Wang, Y., Metcalf, C. A., Sundaramoorthi, R., Shakespeare, W. C., Snodgrass, J. T., Wardwell, S., Dalgarno, D. C., et al. (2005) · Blood · doi:10.1182/blood-2004-12-4771 · Cited by 60
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
Rosti, G., Martinelli, G., & Baccarani, M. (2007) · Nature Medicine · doi:10.1038/nm0107-15a · Cited by 59
Minimal residual disease in chronic myeloid leukemia
Löwenberg, B. (2003) · New England Journal of Medicine · doi:10.1056/nejmp038130 · Cited by 44
Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies
Gambacorti-Passerini, C. B., Gasser, M., Ahmed, S., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403775 · Cited by 35
von Bubnoff, N. C. C., Barwisch, S., Speicher, M. R., Peschel, C., & Duyster, J. (2005) · Cell Cycle · doi:10.4161/cc.4.3.1560 · Cited by 32
BIRB-796 is not an effective ABL(T315I) inhibitor
O’Hare, T., & Druker, B. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1005-1209 · Cited by 19
Ottmann, O. G., Kantarjian, H. M., Larson, R. A., le Courte, P., Baccarani, M., Rafferty, T. S., Weitzman, A., & Giles, F. J. (2006) · Blood · doi:10.1182/blood.v108.11.1862.1862 · Cited by 19
Self-citationNovel compounds with antiproliferative activity against imatinib-resistant cell lines
Lerma, E., Nguyen, V.-A., Wang, T., Tipping, A. J., Melo, J. V., Kufe, D. W., Austin, D. J., & Deisseroth, A. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0307 · Cited by 3
Cited by
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
Ca2+ signalling checkpoints in cancer: remodelling Ca2+ for cancer cell proliferation and survival
Roderick, H. L., & Cook, S. J. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2374 · Cited by 731
Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors
Zhang, J., Adrián, F. J., Jahnke, W., Cowan-Jacob, S. W., Li, A. G., Iacob, R. E., Sim, T., Powers, J., Dierks, C., Sun, F., et al. (2010) · Nature · doi:10.1038/nature08675 · Cited by 597
Target profiling of small molecules by chemical proteomics
Rix, U., & Superti-Furga, G. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.216 · Cited by 575
Rational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503
Metadata
- Authors
- Quintás-Cardama, A., Kantarjian, H., & Cortes, J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-10
- Volume
- 6
- Issue
- 10
- Pages
- 834-848
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1992244448
- Cited by
- 305
- References
- 113
- FWCI
- 3.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.